In a research note, Edison predicted Epidiolex will generate peak sales of $195m in Dravet syndrome, $601m in Lennox-Gastaut and $255 million in TSC, based on a 2018 launch year.

UK-based GW Pharmaceuticals’ Epidiolex looks on course for approval in the US, after a panel of FDA experts unanimously backed it as a treatment for two rare forms of epilepsy. The FDA's ...

Reality: Mixed evidence except for FDA-approved use in epilepsy (Epidiolex). Quality and dosage ... JoAnn Manson of Harvard notes, “Pills aren’t shortcuts for lifestyle choices.” ...